Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

Abstract

Given payer expectations, pharmaceutical companies should continue to take a role in ensuring that they have sufficient capacity to support payers in the design and implementation of innovative pricing agreements.